SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGICS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY

被引：0
|
作者：
Mease, P. J. [1 ,2 ,3 ]
Setty, A. [4 ]
Papp, K. [5 ]
Van den Bosch, F. [6 ]
Tsuji, S. [7 ]
Keiserman, M. [8 ]
Carter, K. [4 ]
Mccaskill, R. [4 ]
Mcdearmon-Blondell, E.
Wung, P.
Tillett, W. [9 ]
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Providence St Joseph Hlth, Seattle, WA USA
[3] Univ Washington, Rheumatol Res, Seattle, WA USA
[4] AbbVie Inc, Immunol, N Chicago, IL USA
[5] K Papp Clin Res & Prob Med Res, Waterloo, ON, Canada
[6] Univ Ghent, Dept Internal Med & Pediat, VIB Ctr Inflammat Res, Ghent, Belgium
[7] Nippon Life Hosp, Dept Orthopaed, Osaka, Japan
[8] Pontifical Catholica Univ Rio Grande Sul, Rheumatol, Porto Alegre, RS, Brazil
[9] Univ Bath, Dept Life Sci, Bath, Avon, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Psoriatic arthritis; Targeted synthetic drugs; Safety;
D O I：
10.1136/annrheumdis-2023-eular.2513
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1539
引用
收藏
页码：1136 / 1137
页数：2
相关论文
共 50 条
  • [1] Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study
    Mease, Philip
    Setty, Arathi
    Papp, Kim
    Van den Bosch, Filip
    Tsuji, Shigeyoshi
    Keiserman, Mauro
    Carter, Kyle
    Li, Yihan
    McCaskill, Reva
    McDearmon-Blondell, Erin
    Wung, Peter
    Tillett, William
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (11) : 2286 - 2297
  • [2] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY
    Mcinnes, I.
    Kato, K.
    Magrey, M.
    Merola, J. F.
    Kishimoto, M.
    Haaland, D.
    Li, Y.
    Liu, Y.
    Liu, J.
    Lippe, R.
    Wung, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1137 - 1138
  • [3] Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
    McInnes, Iain B.
    Kato, Koji
    Magrey, Marina
    Merola, Joseph F.
    Kishimoto, Mitsumasa
    Haaland, Derek
    Chen, Liang
    Duan, Yuanyuan
    Liu, Jianzhong
    Lippe, Ralph
    Wung, Peter
    [J]. RHEUMATOLOGY AND THERAPY, 2023, 10 (01) : 275 - 292
  • [4] Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
    Iain B. McInnes
    Koji Kato
    Marina Magrey
    Joseph F. Merola
    Mitsumasa Kishimoto
    Derek Haaland
    Liang Chen
    Yuanyuan Duan
    Jianzhong Liu
    Ralph Lippe
    Peter Wung
    [J]. Rheumatology and Therapy, 2023, 10 : 275 - 292
  • [5] Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
    Mease, Philip J.
    Lertratanakul, Apinya
    Papp, Kim A.
    van den Bosch, Filip E.
    Tsuji, Shigeyoshi
    Dokoupilova, Eva
    Keiserman, Mauro W.
    Bu, Xianwei
    Chen, Liang
    McCaskill, Reva M.
    Zueger, Patrick
    McDearmon-Blondell, Erin L.
    Pangan, Aileen L.
    Tillett, William
    [J]. RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 903 - 919
  • [6] Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
    Philip J. Mease
    Apinya Lertratanakul
    Kim A. Papp
    Filip E. van den Bosch
    Shigeyoshi Tsuji
    Eva Dokoupilova
    Mauro W. Keiserman
    Xianwei Bu
    Liang Chen
    Reva M. McCaskill
    Patrick Zueger
    Erin L. McDearmon-Blondell
    Aileen L. Pangan
    William Tillett
    [J]. Rheumatology and Therapy, 2021, 8 : 903 - 919
  • [7] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY
    Mcinnes, I.
    Kato, K.
    Magrey, M.
    Merola, J. F.
    Kishimoto, M.
    Haaland, D.
    Chen, L.
    Duan, Y.
    Liu, J.
    Lippe, R.
    Wung, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 260 - 261
  • [8] Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
    Mease, Philip J.
    Lertratanakul, Apinya
    Anderson, Jaclyn K.
    Papp, Kim
    Van den Bosch, Filip
    Tsuji, Shigeyoshi
    Dokoupilova, Eva
    Keiserman, Mauro
    Wang, Xin
    Zhong, Sheng
    McCaskill, Reva M.
    Zueger, Patrick
    Pangan, Aileen L.
    Tillett, William
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03) : 312 - 320
  • [9] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Setty, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Keiserman, M.
    Bu, X.
    Chen, L.
    Mccaskill, R.
    Mcdearmon-Blondell, E.
    Wung, P.
    Tillett, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 836 - 837
  • [10] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, Philip J.
    Setty, Arathi
    Papp, Kim
    Van den Bosch, Filip
    Tsuji, Shigeyoshi
    Keiserman, Mauro
    Bu, Xianwei
    Chen, Liang
    Mccaskill, Reva
    Mcdearmon-Blondell, Erin
    Wung, Peter
    Tillett, William
    [J]. RHEUMATOLOGY, 2023, 62
12345